VCC Adult Trials: HEMATOLOGICAL MALIGNANCY

Leukemia

Go to the Leukemia Page

Lymphoma

Go to the Lymphoma Page

MDS

None Currently Open

Myeloma

Protocol Millenium CO5009: Randomized Phase 3b Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myeloma Who Are Not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation: VELCADE (Bortezomib), Thalidomide, and Dexamethasone (VTD) versus VELCADE and Dexamethasone (VD) versus VELCADE, Melphalan, and Prednisone (VMP)
Primary Investigator: Barbara Grant, M.D.
Contact: Karen Lepuschenko, (802) 656-9924

Protocol CALGB 100104: A Phase III Randomized, Double-Blind Study of Maintenance Therapy with CC-5013 (NSC #703813, IND #70116) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma.
Primary Investigator: Barbara Grant, M.D.
Contact: Karen Wilson, (802) 656-4101

Protocol NovartisCZOL446E2105: A stratified, randomized, open-label, multi-center comparative 2-arm trial of PK, PD, and safety of Zometa infusions administered monthly vs. every 3-months, in multiple myeloma patients with malignant bone lesions, and breast cancer patients with bone metastasis, who have received 9 to 12 doses of Zometa over the prior year.
Primary Investigator: Barbara Grant, M.D.
Contact: Karen Lepuschenko, (802) 656-9924

Hematologic Disorders

Protocol VCC 0406: Platelet Subpopulations and Function in Patients with Hematologic and Oncologic Disorders.
Primary Investigator: Chris Holmes, M.D.
Contact: Karen Wilson, (802) 656-4101

Protocol VCC 0510: Platelet Modulation by Angiogenesis Inhibitors.
Primary Investigator: Chris Holmes, M.D.
Contact: Karen Wilson, (802) 656-4101